Category: Healthcare Finance News

Baylor, Scott & White Health, Memorial Hermann call off merger

The deal was reportedly worth $14 billion and was announced in early October. Meanwhile, the Dignity Health and Catholic Health initiatives mega-merger is complete.

Medicare spending on healthcare for elderly dips, driven by better cardiovascular care

The findings make a fiscal case for increasing prevention efforts among patents of all ages, not just the elderly.

Easing time spent on prior authorization requires industry-wide adoption of electronic transactions

HIMSS19: Leveraging technology to improve prior authorization…

NYU Langone tackles end-of-life care decision-making

NYU Langone embedded a provider-facing screening question into the EHR admission process that was cosigned on admission and at discharge by the attendant of record.

Atul Gawande’s company looking to try new products on employees, trial testimony shows

Plans are for the 1.2 million employees of Amazon, Berkshire Hathaway and JPMorgan Chase, with no current intent to sell to broader market.

Shriner’s Hospital for Children to end inpatient care at Tampa facility, layoff some staff

System said majority of Tampa employees will not be affected; telemedicine and partnerships will be tools to help reach patients in region.

Patients with primary care doctors receive more high-value healthcare, study finds

Policymakers and health system leaders seeking to increase value should consider increasing investments in primary care.

When it comes to new healthcare payment and delivery models, CFOs lack confidence

Finance leaders are worried about the changing landscape, and many feel unprepared for what’s to come.

Democrats, America’s Health Insurance Plans, denounce HHS plan targeting drug rebates

Community Oncology Alliance commends proposal to overhaul what it calls secretive drug rebate system that drives list prices higher.

Health and Human Services wants to end ‘middlemen kickbacks’ in drug pricing by targeting rebates

Under the proposal, drugs would be chosen that have the lowest price, not the ones that offer the highest rebate.